200 related articles for article (PubMed ID: 3422828)
41. [Therapy-related acute non-lymphocytic leukemia (M2) with 7;11 chromosome translocation induced into complete remission by low dose cytosine arabinoside and cytarabine ocfosfate therapy].
Shikoshi K; Shikoshi K; Niitsu N; Takada M; Umeda M
Nihon Ronen Igakkai Zasshi; 1994 Jun; 31(6):468-71. PubMed ID: 8078212
[TBL] [Abstract][Full Text] [Related]
42. All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients.
Visani G; Zauli G; Tosi P; Ottaviani E; Gibellini D; Manfroi S; Celeghini C; Pagliarini C; Bassini A; Tura S
Leukemia; 1994 Dec; 8(12):2183-7. PubMed ID: 7528859
[TBL] [Abstract][Full Text] [Related]
43. Clinical and morphological correlations in acute promyelocytic leukemia.
Valdivieso M; Rodriguez V; Drewinko B; Bodey GP; Ahearn MJ; McCredie K; Freireich EJ
Med Pediatr Oncol; 1975; 1(1):37-50. PubMed ID: 1066521
[TBL] [Abstract][Full Text] [Related]
44. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
45. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
Dekker AW; Nieuwenhuis HK; Verdonck LF
Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
[TBL] [Abstract][Full Text] [Related]
46. Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry.
Yoo KH; Kim HJ; Min YH; Hong DS; Lee WS; Kim HJ; Shin HJ; Park Y; Lee JH; Kim H
PLoS One; 2021; 16(5):e0251011. PubMed ID: 33961640
[TBL] [Abstract][Full Text] [Related]
47. Treatment of adult acute myelogenous leukemia: a pilot study at Chulalongkorn Hospital.
Intragumtornchai T; Sucharitchan P; Swasdikul D; Mahasandhana S; Watananukul P
J Med Assoc Thai; 1991 Jul; 74(7):265-71. PubMed ID: 1765741
[TBL] [Abstract][Full Text] [Related]
48. Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia.
Armstrong SG; Browman GP; Benger AM; Meyer RM; McKay KL; Singh G
Leuk Res; 1994 Sep; 18(9):659-64. PubMed ID: 7934140
[TBL] [Abstract][Full Text] [Related]
49. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT
Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570
[TBL] [Abstract][Full Text] [Related]
50. Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.
Martinelli G; Ottaviani E; Testoni N; Visani G; Diverio D; D'Elia G; Mandelli F; Tura S
Haematologica; 1998 Nov; 83(11):985-8. PubMed ID: 9864917
[TBL] [Abstract][Full Text] [Related]
51. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
52. Acute leukemia in adults: assessment of remission induction with combination chemotherapy by clinical and cell-culture criteria.
Curtis JE; Cowan DH; Bergsagel DE; Hasselback R; McCulloch EA
Can Med Assoc J; 1975 Aug; 113(4):289-94. PubMed ID: 1056807
[TBL] [Abstract][Full Text] [Related]
53. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
[TBL] [Abstract][Full Text] [Related]
54. [Therapeutic results of DCMP therapy (2M-80) in acute non-lymphocytic leukemia--the relationship between the residual leukemic cells and duration of remission].
Moriyama Y; Urushiyama M; Ohnishi M; Koyama S; Hirosawa H; Hanano M; Fuse I; Takai K; Nagayama R; Fujiwara M; Kishi K; Takahashi M; Koike T; Sakai C; Kashimura M; Miura R; Aoyagi A; Sanada M; Hattori A; Shibata A; Shinada S
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1549-54. PubMed ID: 6892201
[TBL] [Abstract][Full Text] [Related]
55. A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.
Mandelli F; Vegna ML; Avvisati G; Amadori S; Spadea A; Cacciola E; Cantore N; De Laurenzi A; De Rosa C; Fioritoni G
Ann Hematol; 1992 Apr; 64(4):166-72. PubMed ID: 1581404
[TBL] [Abstract][Full Text] [Related]
56. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study.
Woods WG; Kobrinsky N; Buckley J; Neudorf S; Sanders J; Miller L; Barnard D; Benjamin D; DeSwarte J; Kalousek D
J Clin Oncol; 1993 Aug; 11(8):1448-57. PubMed ID: 8336184
[TBL] [Abstract][Full Text] [Related]
57. Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16.
Berthold F; Creutzig U; Lampert F
Haematol Blood Transfus; 1987; 30():406-9. PubMed ID: 3476374
[TBL] [Abstract][Full Text] [Related]
58. Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study.
Browman G; Preisler H; Raza A; Syracuse K; Azarnia N; Benger A; Chervenick P; D'Arrigo P; Doeblin T; Goldberg J
Br J Haematol; 1989 Apr; 71(4):493-7. PubMed ID: 2653407
[TBL] [Abstract][Full Text] [Related]
59. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
60. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission.
Tallman MS; Kopecky KJ; Amos D; Dahlberg S; Hewlett JS; Files JC; Coltman CA; Thomas ED; Appelbaum FR
J Clin Oncol; 1989 Mar; 7(3):326-37. PubMed ID: 2645386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
